News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MacuSight, Inc. Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema



10/1/2007 8:38:49 AM

UNION CITY, Calif., Oct. 1 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced positive interim data from a Phase 1 study of its lead product candidate in patients with chronic, clinically significant diabetic macular edema (DME). Results from this prospective study of 50 patients demonstrated that MacuSight's proprietary formulation of sirolimus (rapamycin) was safe and well-tolerated in all doses tested with two different routes of administration. Additionally investigators noted improvements in visual acuity and foveal thickness reductions for up to 180 days following a single administration of sirolimus. These findings were presented at the 40th Annual Meeting of The Retina Society by Mark Blumenkranz, M.D., chairman of MacuSight's scientific advisory board and professor and chairman of the department of ophthalmology, Stanford University School of Medicine.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES